Flecainide contains Flecainide Acetate as its active component. It belongs to the Heart & Blood Pressure therapeutic class and is marketed as a prescription pill, commonly supplied in a 100 mg strength. In Hong Kong, the medication is regulated under the Medicines and Poisons Ordinance and is available only with a doctor’s prescription.
Flecainide is a Class Ic anti-arrhythmic agent. It works by blocking fast sodium channels in cardiac muscle cells, which slows the rapid influx of sodium during the early phase of the heart’s electrical impulse. This action:
Because the drug slows conduction without significantly affecting the repolarisation phase, its effects appear quickly, usually within an hour after oral administration. The medication’s duration of action lasts several hours, allowing twice-daily dosing in many patients.
Flecainide is approved in Hong Kong for the following indications:
These uses reflect the drug’s ability to suppress abnormal rapid heartbeats while preserving overall cardiac contractility.
If a patient has significant coronary artery disease, heart failure, or a history of myocardial infarction, flecainide is generally avoided because the slowed conduction can worsen outcomes.
Current peer-reviewed evidence does not support routine off-label use of flecainide for conditions outside of cardiac arrhythmias. Any experimental application should only occur within a controlled clinical trial and under specialist supervision.
These effects are usually mild and improve with continued therapy or dose adjustment.
Flecainide carries a black-box warning in many jurisdictions for its potential to precipitate life-threatening arrhythmias in patients with structural heart disease.
General advice: Patients should provide a complete medication list, including over-the-counter products and herbal supplements, before starting flecainide.
Administration tips
Missed dose
Overdose
Discontinuation
Patients should contact their healthcare provider promptly if they notice new palpitations, fainting, or worsening dizziness.
This article provides educational information about flecainide and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Concurrent use of multiple anti-arrhythmics can increase the risk of severe conduction disturbances. Combining flecainide with drugs such as amiodarone or sotalol should only occur under specialist supervision, with close ECG monitoring.
Dizziness may signal a transient drop in blood pressure or an emerging arrhythmia. Sit or lie down, avoid standing quickly, and contact your healthcare provider promptly to assess whether dose adjustment is needed.
Some patients report blurred vision or photopsia (flashing lights). These symptoms are typically mild and resolve with continued therapy, but persistent visual changes warrant medical evaluation.
Class Ic agents, including flecainide, have a stronger sodium-channel blocking effect and a slower dissociation rate than Class Ia drugs (e.g., quinidine). This results in a more pronounced slowing of impulse conduction, which is effective for certain arrhythmias but carries a higher pro-arrhythmic risk in damaged hearts.
Yes, provided you keep the medication in its original labelled container, carry a copy of the prescription, and comply with Hong Kong’s drug import regulations. Some countries may require a doctor’s note for chronic prescription medicines.
Patients with a permanent pacemaker may use flecainide, but the drug can still affect underlying conduction tissue. Periodic ECG and device interrogation are recommended to ensure appropriate pacing thresholds.
Early signs include nausea, vomiting, severe dizziness, and visual disturbances. More serious toxicity presents as life-threatening arrhythmias (e.g., ventricular tachycardia) or profound hypotension. Immediate emergency care is essential.
Magnesium may modestly influence cardiac electrophysiology, but typical supplemental doses do not require dose adjustment of flecainide. Nonetheless, disclose all supplements to your prescriber.
Yes, flecainide acetate tablets are marketed generically in Hong Kong and are available in the 100 mg strength. They are therapeutically equivalent to brand-named versions.
Steady-state levels are usually achieved after 4-5 days of twice-daily dosing, reflecting the drug’s half-life of approximately 12-20 hours in individuals with normal renal function.
